The FDA announced the approval of the RadioGenix System.
Research on therapies that may rouse a patient in a persistent vegetative state needs to include the ethical considerations of waking a patient in a state of incomplete recovery.
HIV-positive patients with virological suppression did not have different rates of aging-relating cognitive decline compared with HIV-negative patients.
The FDA has approved an expanded age range for MultiHance contrast agent.
Another case of unusual amnestic syndrome that includes bilateral hippocampal lesions on MRI has been described.
The FDA has accepted Alnylam's New Drug Application for patisiran, and investigational drug for treating hereditary aTTR amyloidosis, for priority review.
In the second half of 2016, there was an increase in the number of birth defects potentially related to Zika virus infection.
TAK-426, and investigational drug for Zika virus, has been granted Fast Track desgination by the FDA.
The HCV treatment, sofosbuvir was found to be effective in treating the Zika virus.
Patients who underwent C7 nerve transfer and rehabilitation experienced better functional improvement than those who underwent rehabilitation alone.
The CES exhibit has presented an impressive array of medical technology.
Due to inadequate blinding in clinical trials, the benefits associated with medical cannabis therapy may be overestimated.
Stimulation of the other brain structures resulted in no significant blood pressure changes among the studied participants.
These are the top 10 medical innovations expected to be seen in 2018.
The automated diagnosis suggestion at the top of the EKG strip is the output of what is known as a decision support system.
Cognitive decline was not accelerated because of gadolinium buildup in the brain.
The American Academy of Neurology has released new clinical practice guidelines addressing the use of cervical and ocular vestibular evoked myogenic potential testing.
Higher-concentration intranasal naloxone has similar efficacy to that of intramuscular naloxone given at the same dose for reversal of opioid overdose.
Nonoptimal infant neuromotor development was linked to genetic risk for schizophrenia, but not bipolar disorder.
Smaller total cerebral brain volume is linked with nonalcoholic fatty liver disease.
In obese adults with T2DM, the rise of brain glucose levels is blunted during hyperglycemia.
Surgeon skill level may be differentiated by force-sensing bipolar forceps and force analysis.
Diagnosis of TB meningitis is challenging, although new, next-generation rapid POC testing holds promise for greatly improved sensitivity.
Abnormalities on neurologic examination were found several years after patients were infected with West Nile virus.
There was a linear link between white matter hyperintensity volume and RA pressure in chronic valvular heart disease.
Infection with the Zika virus may increase the risk for development of Guillain-Barré syndrome.
Withholding negative research results not only skews scientific evidence but also puts into question the whole validity of medical research.
The findings may help to better characterize normative development and altered patterns of brain activity that may serve as biomarkers for neurological conditions.
Although some patients will recover completely after corticosteroid therapy, some will experience multiple relapses and develop related severe functional impairments.
Adolescents seem to be unaware that Adderall is an amphetamine, therefore they underrort their nonmedical amphetamine use.
Neurology Advisor Articles
- Updated Ischemic Stroke Guidelines: Expert Takeaways
- Alternative Genetic Risk Variant for Alzheimer Disease Identified
- Advance Directives for Dementia: Honoring Patient Wishes When You Don't Know What They Are
- Ethical Considerations in New Coma Research
- Poor Sleep Associated With Worse PTSD, Chronic Pain in Youth
- Comparing Reference Points for Deep Brain Stimulation Location in Parkinson Disease
- FDA Approves Clinical Decision Support Tool for Stroke
- US Will Produce Radioisotope for MRI, FDA Says
- Cognitive Decline in Men Linked to Low Serum Sodium
- Solanezumab Every 4 Weeks Does Not Significantly Affect Cognitive Decline in Alzheimer Disease